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HEMATOLOGICAL PROFILE OF  
PEOPLE LIVING WITH HIV/AIDS (PLHA’S) 
INTRODUCTION: 
The HIV epidemic, is a convincing illustration of the balance 
between the power of science and the humanism of modern 
medicine. The epidemic is so serious that between 1981 and 2000, 
21.8 million people had died of HIV/AIDS1. 
Clinically significant hematologic abnormalities are common 
in HIV infection. Hematologic abnormalities are among the most 
common complications of infection with HIV2. These abnormalities 
are due to: 
• Impaired hematopoiesis  
• Immune mediated cytopenias and  
• Altered coagulation mechanisms  
These abnormalities may occur as a result of HIV infection 
itself, as sequelae of HIV related opportunistic infections or 
malignancies or as a consequence of therapies used for HIV 
infection and associated conditions. 
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Despite the availability of various categories of diagnostic and 
monitoring techniques for HIV/AIDs, the costs of it are still 
unaffordable to several people in the resource poor settings. Early 
identification of the hematologic abnormalities would lead to 
appropriate planning of treatment strategies. 
Hence, this study was conducted in order to know the pattern 
of these hematologic abnormalities among PLHA’s. 
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AIMS AND OBJECTIVES 
1. To analyse the hematological profile of people living 
with HIV/AIDS (PLHA’s) 
2. To identify the possible correlation between WHO 
clinical stage and hematological abnormalities if any. 
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REVIEW OF LITERATURE 
Disorders of the hematopoietic system including 
lymphadenopathy, anemia, leucopenia, and/or thrombocytopenia are 
common throughout the course of HIV infection and may be the 
direct result of HIV, manifestations of secondary infections and 
neoplasms, or side effects of therapy. Direct histologic examination 
and culture of lymph node or bone marrow tissue are often 
diagnostic. A significant percentage of bone marrow aspirates from 
patients with HIV infection have been reported to contain lymphoid 
aggregates, the precise significance of which is unknown. Initiation 
of HAART will lead to reversal of most hematologic complications 
that are the direct result of HIV infection. 
Hematologic abnormalities secondary to HIV infection include 
anemia, neutropenia, thrombocytopenia, venous thrombo embolism, 
hemophagocytic syndrome, AIDS - related lymphoma including 
primary effusion lymphoma, castlemann’s disease and rarely 
Hodgkin’s disease and myeloma. 
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ANEMIA: 
Anemia is common in HIV-infected individuals occuring in 
approximately 10 to 20% at initial presentation and diagnosed in 
approximately 70 to 80% of patients over the course of disease3,5. 
The incidence increases with the clinical stage of disease. It is 
dependent of CD4 count and viral load i.e. frequency and severity of 
anemia appear to correlate with HIV related factors such as  
i) CD4 counts less than 200 cells/microlitre.  
ii) Higher plasma HIV-1 RNA levels, and  
iii) History of clinical AIDS defining condition6,7 
On the contrary presence of anemia in HIV infected patient is 
significantly associated with an increased risk of death, and this is 
independent of the CD4 count and viral load8,9. 
In a study among patients receiving no myelosuppressive 
therapies 8% of asymptomatic HIV seropositive patients, 20% of 
those with symptomatic HIV disease, 91% of those with centre for 
disease control (CDC) defined AIDS were anemic10. The viral 
activated transfusion study11,12 found that the frequency of 
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transfusion for anemia decreased after institution of HAART when 
compared to historical controls5. 
CAUSES OF ANEMIA: 
I) Decreased production of red blood cells 
II) Increased red cell destruction 
III) Ineffective production of red cells 
I) Decreased production of red blood cells: 
A decrease in red blood cell (RBC) production may result from 
factors:  
i) suppression of the CD 34+ colony forming unit - 
granulocyte - erythroid - monocyte - macrophage by 
inflammatory cytokines or the HIV virus itself3,4.  
ii) Blunted production of erythropoietin - documented in 
anemic HIV-infected patients, similar to the suppression 
observed in other states of chronic infection or 
inflammation12.  
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iii) Infiltration of the marrow by tumour such as lymphoma13 or 
infection such as mycobacterium avium complex (MAC). 
All these may lead to decreased production of RBC’s.  
In addition, MAC may also be associated with cytokines - 
induced marrow suppression. Involvement of GI tract by various 
infections (or) tumours may lead to chronic blood loss, with eventual 
iron deficiency anemia.  
Another important cause of hypoproliferative anemia in 
patients with HIV infection is medications particularly ART drug 
zidovudine (AZT). AZT, the first licensed anti retroviral agent is 
uniformly associated with macrocytosis (Mean cell volume >100fl), 
which can be used as an objective indication that the patient has 
been compliant with this medication14.  
Transfusion dependent anemia (Hb <8.5g/dl) has been reported 
in approximately 30% of patients with full blown AIDS who were 
receiving AZT at doses of 600mg/day. Incidence of severe anemia is 
only 1%  when the same dose of AZT is used in patients with 
asymptomatic HIV disease15. 
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Infection of the marrow by Parvo virus B19 is another cause of 
hypoproliferative anemia in HIV-infected patients, resulting in 
specific infection of the pronormoblast16,17. Although marrow failure 
affecting all three cell lines has been described with parvovirus B19 
infection, a pure red cell aplasia is the usual consequence. 
Approximately 85% of adults have serologic evidence of prior 
parvo virus infection, but among HIV infected patients it is only 
64%. The diagnosis of parvovirus B19 can be made on marrow 
examination, revealing giant pronormoblasts with clumped 
basophilic chromatin and clear cytoplasmic vacuoles.  
Diagnosis can be confirmed by in situ hybidization using 
sequence-specific DNA probes. Therapy for parovirus induced red 
cell aplasia consists of infusion of intervenous γ-globulin (IVIG) 
from plasma donors. 
ii) Increased red cell destruction: 
Increased red cell destruction may be seen in HIV infected 
patients with Glucose 6 phosphate dehydrogenase (G-6PD) 
deficiency who are exposed to oxidant drugs and in patients with 
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disseminated intravascular coagulation (DIC) or thrombotic 
throbocytopenic purpura18.  
Presence of fragmented RBC’s and thrombocytopenia is seen 
in the latter two conditions and Heinz bodies in G-6PD deficiency. 
Hemophagocytic syndrome has been described in HIV infection19,20. 
The development of autoantibodies, with resultant positive coombs 
test and shortened red cell survival is an additional cause of red cell 
destruction. 
Direct coomb positive test has been reported in 18 to 77% of 
HIV infected patients although actual hemolysis is low21. When 
present, anti-I antibody and anti body against auto-u antigens have 
been described in 64% and 32% of patients respectively22,23.  
A high incidence of positive direct coombs test results has 
been detected in patients with other hypergamma globulinemic states 
indicating that it may be secondary to the polyclonal hypergamma 
globulinemia known to occur in HIV infection24. 
iii) Ineffective production of red cells: 
Folic acid is absorbed in the jejunum and is responsible for 
one carbon transfer reactions. Deficiency leads to megaloblastic 
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anemia and decrease in all three cell lines. HIV infected patients 
who are ill and not eating properly and those with underlying disease 
of the jejunum may be unable to absorb sufficient folic acid. 
Absorption of vitamin B12 requires production of intrinsic 
factor by parietal cells in the stomach with subsequent absorption in 
ileum.  Vitamin B12 malabsorption occurs in HIV infection because 
of myriad of infections and other disorders of small intestine. 
Negative B12 balance has been documented in approximately one 
third of patients with AIDS, the majority being defective 
absorption25.  
Sub acute combined degeneration of the cord occurs in B12 
deficiency and should be considered in HIV infected patients with 
neurologic symptoms. 
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CONSEQUENCES OF ANEMIA IN HIV INFECTION: 
i) Decreased Survival 
ii) Disease Progression 
iii) Impaired quality of life 
i) Decreased Survival: 
Several large cohort studies have shown that anemia is an 
independent risk factor for shorter survival in HIV infected 
patients6,26.  
In the multi state adult and adolescent spectrum of HIV 
disease surveillance project, anemia was found to be associated with 
an increased risk of death for all CD4 ranges5. Risk of death was 
increased by 60% for anemic patients with CD4 count <200 
cells/microlitre. 
Recovery from anemia was shown to be independently 
associated with improved survival. A study of 6725 European HIV 
infected patients showed independent prognostic factors for 
Survivals as: 
i) Hb at base line 
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ii) CD4 count and  
iii) Viral load  
For each 1g/dl decrease in Hb level, the relative hazard of 
death was 1.39 (9.5% confidence interval 1.34-1.43) 
ii) Disease Progression: 
Anemia has been shown to be independently associated with 
rapid clinical progression of HIV infection. In a cohort study factors 
related to disease progression were found as: 
i) most recent Hb level 
ii) CD4 count 
iii) HIV 1 viral load and  
iv) a history of clinical AIDS before initiation of HAART. 
With mild anemia the relative hazard of disease 
progression or death was 2.2 (95% CI 1.6 - 2.9) whereas 
for severe anemia it was 7.1 (95% CI 2.5 -20.1). 
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iii) Quality of life parameters: 
Anemia has been associated with decrease in quality of life 
(QOL) as measured by the linear Analogue self assessment (LASA) 
scale and other such instruments28,29. 
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NEUTROPENIA 
ETIOLOGY: 
Neutropenia is reported in approximately 10% of patients with 
early asymptomatic HIV infection and in more than 50% of 
individuals with more advanced HIV-related immunodeficiency3,4,30. 
Decreased colony growth of the progenitor cell colony forming unit - 
granulocyte - Macrophage31 may lead to decreased growth of both 
granulocytes and monocytes.  
Soluble inhibitory substances produced by HIV-infected cells 
have been noted to suppress neutrophils production in vitro. 
suggesting that autoimmunity plays a part in the development of 
neutropenia in HIV infection32. 
However studies have shown that the presence of neutrophil 
bound Ig correlates best with stage of disease rather than neutropenia 
per se33.  
Decreased serum levels of granulocyte colony stimulating 
factor (G-CSF) have been described in HIV seropositive subjects 
with afebrile neutropenia (<1000/microlitre) suggesting that a 
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relative deficiency of this growth factor may contribute to persistent 
neutropenia34.  
The other causes of neutropenia in HIV infection includes 
i) presence of opportunistic infections. 
ii) malignancies and  
iii) HIV related myelodysplasia affecting marrow function35. 
Myelosuppression and neutropenia may also result from any of 
the medications used. HIV infection also causes decreased function 
of granulocytes and monocytes. Abnormal FC processing by 
macrophages has been described.  
Decreased opsonization and intra cellular killing of bacterial 
or fungal organisms by granulocytes have been noted36. 
CONSEQUENCES OF NEUTROPENIA: 
Multiple studies have shown that the risk of bacterial infection 
rises when the absolute neutrophil count (ANC) falls below 
1000/microlitre and increases further when the ANC falls below 
500/mircolitre37.  
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Moore and colleagues38 found that the risk of bacterial 
infection increases to 2.3 fold and 7.9 fold in HIV infected 
individuals with ANC less than 1000/ml and 500/ml respectively.  
On multivariate analysis the severity and duration of 
neutropenia were found to be significant predictors of the incidence 
of hospitalization for serious bacterial infection39. 
On multivariate analysis the three factors independently 
associated with infectious complications were  
i) Presence of a central venous catheter 
ii) Neutropenia in the past 3 months and  
(i) A lower nadir of granulocyte count. 
Among patients with medication associated neutropenia, the 
most common cause was AZT, followed by cotrimoxazole and 
ganciclovir. Neutropenia was less likely to be associated with 
infection in these patients than in individuals on cancer 
chemotherapy40. 
 
17
LYMPHOPENIA 
The immune system of patients with HIV infection are 
characterized by a profound increase in lymphocyte turnover that is 
immediately reduced with effective and retroviral therapy. Studies 
utilizing in vivo or in vitro labelling of lymphocytes in the S-phase 
of the cell cycle have demonstrated a tight correlation between the 
degree of lymphocyte turnover and plasma levels of HIV RNA. This 
increase in turnover is seen in CD4+ and CD8+ T lymphocytes as 
well as B lymphocytes and can be observed in peripheral blood and 
lymphoid tissue. Mathematical models derived from these data 
suggest that one can view the lymphoid pool as consisting of 
dynamically distinct subpopulations of cells that are differentially 
affected by HIV infection. A major consequence of HIV infection 
appears to be a shift in cells from a more quiescent pool to a pool 
with a higher turnover rate. It is likely that a consequence of a higher 
rate of turnover is a higher rate of death. The role of the thymus is 
controversy. While some data point to an important role for the 
thymus in maintaining T cell numbers and suggest that impairment 
of thymic function may be responsible for decline in CD4 cell count 
seen in the setting of HIV infection, other studies have concluded 
 
18
that the thymus plays a minor role in HIV pathogenesis. Among the 
data supporting an important role for the thymus are those that 
demonstrate an increase in the levels of T cell receptor excision 
circles (TRECs) following initiation of antiretroviral therapy. 
TRECs are a byproduct of T cell development and represent 
episomal fragments of DNA that are excised during T cell receptor 
gene rearrangement. Levels of TRECs will be the net result of 
changes in thymic output and changes in T cell turnover will lead to 
an increase in levels of TRECs. While it is clear that levels of 
TRECs increase following initiation of antiretorival therapy, it is not 
clear whether this is a consequence of increased thymic output or 
decreased T cell turnover.  
Increases in both CD4 and CD8 cell death and impairment in 
function are the sine qua non of HIV infection. IL-2 partially 
corrects the impaired lymphocyte proliferation and cytotoxicity seen 
in HIV infection in vitro.  
It also partially blocks the tendency of lymphocytes obtained 
from HIV infected patients to undergo apoptosis41. In phase I trials 
of IL-2 in HIV infected patients, it increased CD4 cell number and 
improved lymphocyte function41.  
 
19
The development of a long acting polyethylene glycol 
modified IL-2 which increases the half life by 10-15 fold allows 
intermittent administration of the drug. 
In 1993, revised classification system for HIV infection and 
expanded AIDS surveillance case definition for adolescents and 
adults, CD4 cell categorization has been done as, 
i) >500/micro litre 
ii) 200-499/micro litre 
iii) <200/micro litre 
CONSEQUENCES OF LYMPHOPENIA: 
CD4 T cell count is accepted as best indicator of the 
immediate state of immunologic competence in patients with HIV 
infection. Patients with CD4 T cell counts <200/microlitre are at 
high risk of infection with p.carinii while those with counts <50/ 
microlitre are at risk of cytomegalo virus and mycobacterium avium 
(MAC) complex infection. Hence CD4 T cell measurements should 
be done at the time of diagnosis and every 3-6 months thereafter. 
CD4 T cell count <350/ microlitre is an indication of initiating 
anti retroviral therapy and decline in count >25% from the base line 
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CD4 count warrant change in therapy. Thrush due to candidal and 
oral hairy leukoplakia occur in CD4 count < 300/micro litre. 
All patients with HIV infection about to undergo splenectomy 
should be immunized with pneumococcal polysaccharide. It should 
be noted that, in addition to causing an increase in the platelet count, 
removal of the spleen will result in an increase in the peripheral 
blood lymphocyte count, making CD4+ T cell counts unreliable. In 
this setting, the clinician should rely on the CD4+ T cell percent for 
making diagnostic decisions with respect to the likelihood of 
opportunistic infections. A CD4+ T cell percentage of 15 is 
approximately equivalent to a CD4+ T cell count of 200/µl. 
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THROMBOCYTOPENIA 
Thrombocytopenia is relatively common during the course of 
HIV infection, occuring in approximately 40% of patients and 
serving as the first symptom or sign of infection in approximately 
10%42,43. Development of thrombocytopenia was associated with  
i) history of clinical or immunologic AIDS  
ii) injection drug abuse  
iii) history of anemia or lymphoma  
iv) being an American or African descent.  
After controlling for multiple factors, thrombocytopenia was 
significantly associated with shorter survival (risk ratio 1.7)43  
The incidence of thrombocytopenia, defined as a platelet count 
less than 150,00/ml, was evaluated among 1990 HIV-infected and 
553 HIV-negative women who were part of The Women’s 
interagency HIV Study (WIHS). At baseline, 15 percent of HIV-
positive women were thrombocytopenic compared to 1.6 percent of 
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HIV-negative women (p<0.001). Factors associated with increased 
risk of thrombocytopenia included  
(1) HIV infection, 
(2) Low CD4 levels 
(3) Increasing viral load 
(4) Smoking, and 
(5) being an American of European descent. 
The study also found thrombocytopenia was significant 
predictor of both all - cause and AIDS-related mortality among 
women infected with HIV. Thus, HIV-infected women with a 
platelet count less than 50,000/ml had a fivefold increased risk of 
death from any cause compared to women with normal platelet 
courts (hazard ratio [HR] 5.10, 95% CI 2.71-9.58) and an 
approximately threefold increased risk of death from AIDS (HR 
3.36, 95% CI 1.44-7.83). 
CAUSES OF HIV-RELATED IMMUNE  
THROMBOCYTOPENIC PURPURA (ITP) 
i) Increased platelet destruction 
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ii) Decreased platelet production 
iii) Infection of Megakarocytes by HIV 
iv) HIV related thrombotic thrombocytopenic purpura (TTP) 
i) Increased platelet destruction: 
As in ITP, HIV infected patients with ITP also demonstrate 
increased platelet destruction via phagocytosis by Macrophages in 
the spleen44. Presence of platelet specific antibodies characterized as 
anti group IIb/IIIa have been detected in HIV infected patients45.  
However cross reactive antibody between HIV Gp 160/120 and 
platelet GP IIb/IIIa may be operative in immune destruction of 
platelets in HIV related ITP. Absorption of immune complexes 
against HIV into platelet FC receptor, providing ‘free’ FC portion 
for macrophage binding and phagocytosis45. 
ii) Decreased platelet production: 
Mean platelet survival was significantly decreased in patients 
with HIV-ITP occuring to same extent in patients receiving AZT and 
those untreated. Mean platelet survival also was significantly 
decreased in HIV infected patients with normal platelet count.  
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Mean platelet production was significantly decreased in 
patients with untreated HIV ITP although those receiving AZT 
demonstrated a subsequent rise in platelet production. 
iii) Infection of Megakarocytes by HIV: 
Reduced production of platelets may be due to direct infection 
of megakaryocyte by HIV. Human megakaryocytes bear a CD4+ 
receptor capable of binding HIV47 and HIV 1 can be internalized by 
human Megakacyocytes48.  
The HIV 1 coreceptor CXCR4 is present on Megakayocytic 
progenitors, Megakaryocytes and platelets. Using in situ 
hybridization HIV transcripts have been detected in megakaryocytes. 
Specific ultra structural damage in HIV infected megakaryocytes 
consisting of blebbing and vacuolization of surface membrane50. 
iv) HIV related thrombotic trrombocytopenic purpura (TTP) 
HIV infection is associated with an increased incidence of TTP 
and hemolytic uremic syndrome characterized by Microangiopathic 
hemolytic anemia and thrombocytopenia with or without end organ 
failure. HIV related TTP generally has milder cause and better 
response to therapy than classical TTP51. 
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HIV can infect endothelial cells, and viral P24 antigen has been 
detected in splenic endothelial cells, spinal cord specimens and in 
bone marrow microvascular endothelial cells52.  
TNF-α and IL-1β are increased in HIV infection could 
potentially lead to increases in endothelial expression of adhesion 
molecules such as vascular cell adhesion molecule-1, intercellular 
adhesion molecule and E-selectin promoting localization of 
inflammatory cells to endothelium. Endothelial cells from small 
blood vessels undergo apoptosis when exposed to plasma from 
patients with TTP53. 
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MATERIALS  
SUBJECTS 
 All patients with HIV infection attending Govt. General 
Hospital between May 2005 - May 2007. 
PERIOD OF STUDY 
May 2005 to May 2007. 
DESIGN OF STUDY 
Prospective Study 
ELIGIBILITY CRITERIA  
1. All patients with HIV infection 
2. HIV infection proven by ELISA & western blot assay. 
EXCLUSION CRITERIA 
1. Chronic infection like tuberculosis 
2. Alcoholics 
3. Worm infestations 
4. Chronic kidney disease 
5. Drug intake (phenytoin) 
6. Patient on anti retroviral therapy 
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METHODOLOGY 
All patients with HIV infection attending Govt. General 
Hospital during the study period were evaluated for the conditions 
which could alter the Hematological parameters and if found so, they 
were excluded from the study. 
Those included in the study were investigated for Hb% total 
count, differential count, ESR and platelet count. CD4 count done by 
flow cytometric analysis was obtained. They were staged as per the 
WHO clinical staging given by the National AIDS control 
organisation (NACO) 
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65Normal Values of 
parameters Assessed Male Female 
Erythrocyte 
sedimentation rate 1 to 25 mm/Hr 
0 to 17  
mm /Hr 
Haemoglobin 13.5 to 17.5 g/dl 12.0 to 16.0 g/dl 
Total leucocyte count 4.5 to 11.0 x 103/mm3 
Neutrophils 40 to 70% 
Lymphocytes 22 to 44 % 
Monocytes 4 to 11% 
Eosinophil 0 to 8% 
Differential count 
Basophil 0 to 3 % 
CD4 count <950 cells/microlitre 
Platelet count 1.5 to 3.0 lakh / mm3 
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WHO CLINICAL STAGING (NACO) 
• Stage I - Asymptomatic  
- Persistent generalised lymphadenopathy 
- Performance scale 1:asymptomatic normal activity. 
• Stage II - Wt. loss < 10% of body weight  
- Minor muco cutaneous manifestation  
(seborrheic dermatitis, fungal nail infection, 
recurrent oral ulcers, angular chelitis) 
- Herpes zoster (within last 5 years)  
Recurrent upper resp. infection (bacterial sinusitis)  
Performance scale 2: Symptomatic, normal activity. 
• State 3 - Wt loss > 10% body weight  
unexplained chronic diarrhea >1 month unexplained 
fever (intermittent/continuous) > 1 month 
- Oral Thrush 
- Oral hairy leukoplakia 
- Pulmonary TB within past 1 year. 
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-  Severe bacterial infection (preumonia, pyomyositis) 
- Performance Scale 3:  bed ridden for <50% of day in last 
1 month. 
• Stage 4 - HIV wasting synd (>10% BW loss + Unexplained 
fever (or) Unexplained diarrhoea >1 month chronic 
weakness) 
- Pneumocystitis carnii pneumonia 
- Toxoplasmosis of brain 
- Cryptosporidiasis with diarrhea >1 month 
- Cyptococcosis (extra pulmonary) 
- Cytomegalo viral disease of organ other than liver, 
spleen and lymph node 
- Herpes simplex infection, Mucocutaneous  
>1 month (or) visceral 
- Progressive multifocal leukoencephalopathy 
- Disseminated endemic mycosis, histoplasmosis, 
Coccidiodomycosis 
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- Candidiasis of oesophagus, trachea, bronchi lung 
- Atypical; Mycobacterial infection 
- Non typhoid salmonella septicaemia 
- Extra pulmonary tuberculosis  
- Lymphoma  
- Kaposi sarcoma 
- HIV encephalopathy 
- Performance scale 4: Bed ridden for >50% of day in 
last 1 month. 
STATISTICAL ANALYSIS 
Data entry and analysis done values are presented as Mean+ 
Standard deviation and median +Q (interquartile range) as 
appropriate. Percentages were used to describe the proportions of 
discrete variables. A p value of <0.05 was considered statistically 
significant. 
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OBSERVATIONS 
100 patients with HIV infection were included in the study 
after excluding for all possible parameters that could affect the blood 
cell counts. Before the initiation of anti retroviral therapy they were 
investigated for Hb, total count, differential count, CD4 count, 
platelet count and erythrocyte sedimentation rate (ESR). The 
observations of the study are as noted below: 
AGE DISTRIBUTION: 
Table No.1 
Age (in yrs) n % 
21-25 2 2.0 
26-30 15 15.0 
31-35 29 29.0 
36-40 27 27.0 
41-45 20 20.0 
45-50 5 5.0 
51-55 2 2.0 
The mean age was found to be 36.85+6.29. 
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SEX DISTRIBUTION: 
Table No. 2 
 n % 
Male 60 60% 
Female 40% 40% 
WHO STAGE DISTRIBUTION: 
Table No.:3 
Stage n % 
I 4 4% 
II 29 29% 
III 55 55% 
IV 12 12% 
Majority of them were in Stage III and least of them were in 
Stage I. 
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TOTAL COUNT DISTRIBUTION: 
Tabole No:4 
Total count 
(cells/mm3) n % 
2000-3000 9 9% 
3001-4000 22 22% 
4001-5000 11 11% 
5001-6000 13 13% 
6001-7000 8 8% 
7001-8000 14 14% 
8001-8000 16 16% 
9001-10000 7 7% 
The mean total count was found to be 587+ 2210 cells / mm2 
out of the 100 patients 41 of them had leucopenia. 
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DIFFERENTIAL COUNT 
In our study the differential count distribution showed  
• neutropenia in 30 patients  
• lymphocytopenia in 30 patients and  
• monocytopenia in 20 patients.  
Table No. 5 
White Blood Cells mean 
Neutrophils 54+12.6% 
Lymphocytes 29.8+8.3% 
Monocytes 6.76+4.1% 
Eosinophils 2.36+3.79% 
Basophils 0% 
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CD-4 COUNT DISTRIBUTION 
Table No. 6 
CD4 Count  
(Cells/microlitre) n % 
<200 87 87.0 
200-499 13 13.0 
> 500  0 0 
The median CD-4 count was 89 cells/microlitre. 
Almost all the patients enrolled in our study had CD4 count 
<200/microlitre with only a minor fraction having counts 
>200/microlitre. 
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CD 4 COUNT  & LYMPHOCYTOPNEIA: 
Table No:7 
CD4 Count  
(Cells/microlitre) n % 
<200 30 100% 
200-499 0 0 
> 500 0 0 
All patients who had lymphocytopenia were having CD4 count 
<200/microlitre. This establishes the relationship between 
lymphocytopenia and low CD4 counts. 
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PLATELET COUNT DISTRIBUTION 
Table No : 8 
Platelet Count 
(Lakh/mm3) n % 
<0.5 0 0 
0.5 - 0.99 21 21.0 
1.00 - 1.49 19 19.0 
1.50 - 1.99 37 37.0 
2.00 - 2.49 15 15.0 
2.50 - 2.99 7 7.0 
> 3 1 1.0 
The mean platelet count was 1.56 + 0.35 lakh / mm3 
thrombocytopenia was found in 40 patients. 
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ERYTHROCYTE SEDIMENTATION RATE 
Table : 9 
Elevated ESR (mm/hr) n % 
Male 41 21.0 
Female 30 20.0 
 
The mean value ESR was 24.63 + 10.92 mm /hr. Elevated ESR 
was found in 71%. ESR has not much of diagnostic value and 
therefore can be elevated in any chronic inflammation (or) infection. 
Hence, this finding may not be that significant. 
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HEMOGLOBIN DISTRIBUTION 
Table No. 10 
Hemoglobin g/dll Male Female % 
8.0 - 8.99 1 1 2.0 
9.0 - 9.99 10 3 13.0 
10.0 - 10.99 12 11 23.0 
11.0 - 11.99 16 9 25.0 
12.0 - 12.99 16 13 29.0 
13.0 - 13.99 8 0 08.0 
The mean Hb value was 11.40 + 1.36 g/dl. 
Table No: 11 
Sex Anemia % 
Male 55 87.3% 
Female 24 64.9% 
Male were found to have anemia more commonly than female 
patients. 
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WHO STAGE WISE DISTRIBUTION OF HAEMATOLOGICAL 
ABNORMALITIES 
Table : 12 
Abnormalities I II III IV P 
Leucopenia 2 12 21 6 0.87 
Neutropenia 2 9 16 2 0.62 
Lymphocytopenia - 9 18 3 0.56 
Moncytopenia - 5 12 4 0.49 
Thrombocytopenia 2 12 20 6 0.57 
The WHO clinical stage wise analysis of the Hematologic 
abnormalities were not found to be statistically significant. Hence 
any possible association between WHO stage and cytopenias could 
not be found. 
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WHO STAGING & ANEMIA 
Table : 13 
Anemia I II III IV P 
Male - 12 35 8 0.04 
Female 0 10 13 1 0.005
The WHO clinical stages and anemia correlation was found to 
be statistically significant. Hence a possible relationship found 
between anemia & WHO stages. 
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DISCUSSION 
The observation made in the PLHAs with respect to 
Hemoglobin total count differential count, platelet count, CD4 count, 
erytrocyte sedimentation rate and WHO stages were analysed and 
the following inferences were drawn. 
AGE DISTRIBUTION 
The mean age of the study population was 36.85+ 6.29 yr. 
About 56% of them were in 31-40 year age group i.e., age at the 
diagnosis of HIV infection.  
As per the data released by Tamil Nadu State AIDS control 
society (TANSAC) about 50% of HIV infected patients belonged to 
30 - 49 years at the time of diagnosis (54).  
In the western countries about 36% of them were in the 35-44 
years age group at the time of diagnosis, which happens to be the 
Major age group affected (55). 
Our data is in concordance with these data. 
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SEX DISTRIBUTION 
In our study population 60% were males and 40% females. The 
M:F ratio was 3:2. The sex ratio of PLHA is at the time of diagnosis 
was 8:3 in India(54) and 7:3 in western countries(55).  
The ratio was altered in our study probably, because more 
males got excluded who were alcoholics. Hence our sex ratio 
differed from those of the surveillance reports. 
WHO STAGE DISTRIBUTION 
Majority of the PLHA’s (about 55%) belonged to stage III at 
the time of diagnosis whereas only 4% were in stage I. Hence the 
diagnosis of HIV infection was considerably less in the 
asymptomatic stage and most of them were diagnosed only with 
features of full blown AIDS and Opportunistic infections. 
This implies the fact that, most of the PLHA’s at diagnosis had 
full blown AIDS and hence would develop most of the complications 
and opportunistic infections. Initiation of retroviral therapy would 
only add on to the morbidity. 
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TOTAL COUNT ABNORMALITIES 
The mean total count in our study was 5872 +2210 cells / mm3. 
The total count varied between 2000 to 10,200 cells/mm3. 41% of 
them had leucopenia.  
The percentage of PLHA’s with leucopenia at the time of 
diagnosis was found to 16% and 25% by Amballi et al (56) and 
Amanda(57) et al respectively. Erhabor et al, in his study on the effect 
of anti retroviral therapy an hemotological profile of people PLHA’s 
found leucopenia in 62%(58). 
Higher incidence of leucopenia in our study may be due to the 
diagnosis of HIV infection at advanced stage. This again reiterates 
the fact that diagnosis of HIV infection at advanced stage would 
increase the incidence of complication. 
The awareness campaigns and counselling programs has to be 
intensified, so that the diagnosis of HIV infection can be done at 
earlier asymptomatic stage. 
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NEUTROPENIA 
The mean neutrophil count was 54 + 12.6% and in our study 
21% had neutropenia. Where as Amballi et al found 42.4% of 
PLHA’s to have neutropenia at the time of diagnosis of HIV 
infection(56). 
In our study, out of the 21 persons who had neutropenia, 18 
were in advanced stage of HIV disease (stage III & IV) and 2 were 
in early asymptomatic stage of HIV infection (Stage I). Zon and  
groopman noted neutropenia in 13% of asymptomatic HIV infected 
patients and in 44% of those with frank CDC - defined AIDS (4).  
In the multistate adult and adolescent spectrum of HIV disease 
surveillance project neutropenia was detected in10% and 50% of 
asymptomatic patients and advanced stage of HIV disease patients 
respectively(5).  Hence the occurence of neutropenia was lesser  
in our study. 
In our study more patients in advanced stage of HIV infection 
were having neutropenia. This poses them at the increased risk of 
developing opportunistic infections. 
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LYMPHOCYTOPENIA & CD4 COUNT 
The mean lymphocyte count was 29.82 + 8.3% and the median 
CD4 count was 89 cells/micro litre. CD4 count varied between 6 
cells to 459 cells/ml Lymphocytopenia was found in 30% of the 
PLHA’s and CD4 count <200 cells in 87% of the patients. 
In the study conducted by Amballi et al the median CD4 count 
was 160 cells. They detected lymphopenia and CD4 count 
<200/microlitre in 24.3% and 62.8% respectively(56). 
In our study majority of the PLHA’s (67%) were in advanced 
stage (III & IV) of HIV infection and hence higher incidence of 
lymphocytopenia and CD4 <200/microlitre.  
The findings of low CD4 count in 87% of patients and 
lymphocytopenia in 30% is in accordance with WHO document an 
clinical staging of HIV / AIDS for adults and adolescents, which 
ascertained both lymphopenia and CD4 cells depletion in HIV / 
AIDS(59) 
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THROMBOCYTOPENIA 
Platelet count varied between 0.5 to 2.8 lakh/mm3 and the 
mean count was 1.56 + 0.35 lakh/mm3. Thrombocytopenia was 
founds in 40% of the PLHA’s is our study. In his study conducted 
among HIV positive pregnant women khandekar et al, found 
thrombocytopenia in 9% of them(60). 
Pechere et al detected thrombocytopenai in 40% of HIV 
infected patients during the course of the disease and as the first 
symptoms or sign of HIV infection in approximately 10%(42). 
Murphy et al concluded that thrombocytopenia was found in 
30% (6 of 20) of patients with advanced HIV disease and 8% (5 of 
59) in those with asymptomatic HIV infection(61).  In our study it was 
found in 38% (26 of 67) and 42% (14 of 33) of advanced HIV 
disease and asymptomatic HIV infection respectively. 
Savona et al concluded that in HIV infection, early stages may 
have decreased platelet count due to decreased survival and in late 
advanced disease due to marrow failure(62). 
 
49
ANEMIA 
The mean Hemoglobin in our study was 11.4 +1.36 g/dl and it 
varied between 9g/dl to 14g/dl. In our study 79 patients had anemia 
out of which 55 (87.3%) were males and 24 (64.9%) were females. 
The occurrence of anemia was found to be more common among 
males. 
Amballi et al found anemia in 52% of PLHA’s (56). Anemia 
was reported as a consistent hematological abnormality in HIV/AIDs 
by Ogun et al (63). Mitsuyasu et al and Zon et al detected anemia in 
approximately 10 to 20% at initial presentation and in 70 to 80% 
over the course of HIV infection (3,4). 
Anemia is an independent predictor of survival in HIV 
infection and mortality is increased by 60% in anemia patients with 
CD4 <200/ microlitre(26). In our study 79% had anemia and 87% had 
CD4 <200/ml. This high lights the possibility of increased mortality 
in our set of patients. The institution of HAART in these patients has 
the chance of converting them into transfusion dependent anemia 
patients. 
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ERYTHROCYTE SEDIMENTATION RATE 
The mean ESR was 24.63 + 10.92 mm/hr and varied between 
10 to 50 mm/hr. Elevated ESR was found in 41% of the PLHA’s 
Amballi et al found elevated ESR in 95% of his patients with HIV 
infection(56).  
The prominent elevation of ESR in all these patients is not 
surprising. Although ESR is neither sensitive not specific when used 
as a general screening test, it is usually elevated in the presence of 
infectious disease and chronic illness(64). 
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WHO STAGES & HEMATOLOGIC ABNORMALITIES 
The analysis of the association between WHO staging of AIDS 
and thrombocytopenia, neutropenia, lymphocytopenia, leucopenia 
were not statistically significant. 
In contrast the correlation between anemia and WHO staging 
was statistically significant. The occurrence of anemia was 75%  
(22 of 29) in stage II, 87% (48 of 55) in stage III and 75% (9 of 12) 
in stage IV. As such occurrence of anemia was higher in all stages, 
slightly higher in stage III. 
Sulliram et al in the multistate Adult and adolescent spectrum 
of HIV disease surveillance project reported that the incidence of 
anemia increased with clinical stages of disease in HIV infection. 
They found anemia in 3%, 12% and 27% among those with HIV 
infection alone, immunologic AIDS (CD4<200/ml or CD4% <14%) 
and clinical AIDS respectively(5). 
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CONCLUSION 
 100 PLHA’s were analysed for the Hematological 
abnormalities in HIV/AIDs. 
 Majority of them were in stage III (55%) and had CD4 
count <200/microlitre (87%). 
 Leucopenia was found in 41% of them. 
 Neutropenia was detected in 29%. 
 Thrombocytopenia was found in 40% 
 Anemia and elevated ESR detected in 79% and 71% 
respectively. 
 Lymphocytopenia was detected in 30% of PLHA’s who 
also had low CD 4 count as per the WHO documents. 
 The analysis of correlation between WHO staging and 
hematologic abnormalities revealed statistically 
significant relation only with anemia. 
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MASTER CHART 
Differential Count Sl. 
No. Name Age Sex 
WHO 
Stage 
Total 
count 
(per mm3) P% L% M% E% B%
Platelet 
Count  
(lakh/mm3)
CD4 
Count
(per µl)
Hb  
(g/dl) 
ESR  
at 1 hr 
1. Vijaya 34 F III 8400 64 32 4 0 0 0.75 38 11.2 11 
2. Ravikumar 34 M III 3400 50 45 5 0 0 0.58 58 10.2 25 
3. Ponnurangam 44 M III 9400 66 32 2 0 0 1.6 26 12.4 30 
4. Ramaswamy 38 M IV 6600 70 30 0 0 0 1.5 55 11.2 36 
5. Dhanalakshmi 32 F III 3000 35 15 10 0 0 1.55 17 14.0 35 
6. Mani 36 M II 4100 39 19 15 5 0 1.65 86 13.5 18 
7. Jona 34 M III 4200 38 20 10 4 0 2.0 171 14.0 25 
8. Shanmugam 35 M III 3900 40 20 10 10 0 1.8 79 13.0 15 
9. Pencil Nagaiah 29 M III 3200 36 21 10 10 0 1.9 53 14.0 20 
10. Narayanan 40 M II 8600 61 32 7 0 0 2.1 23 12 35 
11. Dhanabalan 36 M II 8600 61 33 6 0 0 2.7 18 12 15 
12. Sagayaraj 37 M II 4000 60 35 5 0 0 1.6 179 11.8 20 
13. Sugumaran 41 M IV 3900 70 28 2 0 0 0.8 123 12.0 26 
14. Venkatesan 34 M IV 2600 55 25 10 5 0 0.65 11 13.0 20 
15. Shanthi 28 F III 8100 63 35 2 0 0 1.7 9 10 45 
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Differential Count Sl. 
No. Name Age Sex 
WHO 
Stage 
Total 
count 
(per mm3) P% L% M% E% B%
Platelet 
Count  
(lakh/mm3)
CD4 
Count
(per µl)
Hb  
(g/dl) 
ESR  
at 1 hr 
16. Balasubramanian 41 M III 7200 66 33 1 0 0 1.8 15 11 30 
17. Manickam 32 M IV 8900 63 32 5 0 0 1.9 9 12 35 
18. Vasantha Kumari 26 F IV 5200 48 52 0 0 0 1.7 117 12 40 
19. Geetha 32 F III 6000 70 31 3 0 0 1.8 59 11 50 
20. Babu 38 M III 8900 66 31 5 0 0 1.75 153 11.5 45 
21. Gunasekar 34 M III 6000 65 30 5 0 0 1.6 191 12.0 30 
22. Annamalai 30 M II 7100 70 29 1 0 0 1.6 159 11.2 35 
23. Masthan 50 M III 8100 64 32 4 0 0 2.1 102 10.6 35 
24. Kavitha 42 F I 7100 60 35 5 0 0 2.0 184 12.2 30 
25. Barathy 21 F III 7400 63 32 5 0 0 0.60 6 10.2 35 
26. Subramani 37 M III 9400 55 40 5 0 0 0.70 77 12.5 18 
27. Sivaraman 40 M III 3300 35 20 15 5 0 2.5 160 12.0 10 
28. Thirunavukarasu 2.8 M II 4000 38 21 16 6 0 2.8 103 11.0 12 
29. Lakshmi 34 F II 7800 61 35 4 0 0 1.6 125 10.2 30 
30. Vimala 41 F III 3000 39 20 20 10 0 2.5 57 12.0 15 
31. Nathan 48 M III 3100 36 21 20 9 0 2.7 132 13.0 16 
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Differential Count Sl. 
No. Name Age Sex 
WHO 
Stage 
Total 
count 
(per mm3) P% L% M% E% B%
Platelet 
Count  
(lakh/mm3)
CD4 
Count
(per µl)
Hb  
(g/dl) 
ESR  
at 1 hr 
32. Dhanasekar 36 M III 8600 58 37 5 0 0 0.55 37 11 30 
33. Devakumar 32 M III 7900 76 21 3 0 0 0.65 194 10.2 5 
34. Geetha 38 F I 2600 38 25 10 15 0 2.8 205 14.0 10 
35. Chinna Thai 27 F III 8600 64 32 4 0 0 2.7 195 11.2 36 
36. Latha 30 F I 3900 35 22 10 10 0 1.8 177 12.0 10 
37. Kishna Moorthy 30 M II 4000 39 21 10 10 0 0.80 44 13.5 10 
38. Mangilal 40 M III 4100 60 20 15 5 0 1.9 22 14.0 10 
39. Antony Samay 35 M II 3800 63 21 15 2 0 0.70 32 13.6 10 
40. Selvam 42 M II 3600 39 25 10 10 0 1.85 133 12.0 15 
41. Chellammal 29 F II 3400 35 15 10 10 0 1.1 123 13.0 19 
42. Subashree 37 F I 7800 61 34 5 0 0 1.2 191 13.2 25 
43. Kuppu 35 F II 7600 52 40 8 0 0 1.95 19 11.9 20 
44. Gurunathan 38 M III 3000 39 21 10 10 0 1.75 28 12.0 25 
45. Selvakumar 38 M III 2000 38 21 9 8 0 1.65 87 11.0 26 
46. Arumugam 40 M IV 2100 37 21 11 9 0 0.75 121 10.0 30 
47. Muthu 41 M III 8400 58 38 4 0 0 1.70 459 10 36 
 
67
Differential Count Sl. 
No. Name Age Sex 
WHO 
Stage 
Total 
count 
(per mm3) P% L% M% E% B%
Platelet 
Count  
(lakh/mm3)
CD4 
Count
(per µl)
Hb  
(g/dl) 
ESR  
at 1 hr 
48. Varadharaju 45 M IV 2600 35 20 11 6 0 0.65 17 10 25 
49. Shanmugakani 32 F II 3500 38 21 10 7 0 1.80 205 11.0 28 
50. Sekar 44 M III 8600 67 28 5 0 0 0.65 30 10.6 16 
51. Durairaj 38 M III 3700 36 20 11 8 0 1.4 59 10.0 15 
52. Mariamma 33 F III 3800 39 21 10 7 0 1.95 99 11.0 16 
53. Baby 40 F III 4400 37 20 9 7 0 1.0 38 9 20 
54. Sairam 47 M III 7000 70 26 4 0 0 1.90 57 9 25 
55. Elumalai 40 M III 4300 38 20 10 6 0 0.95 43 10 20 
56. Musthapa 43 M III 4100 37 21 9 8 0 1.70 81 10 25 
57. Syed Ahmed 42 M II 4000 39 20 8 8 0 1.1 71 11.0 28 
58. Kuppusamy 38 M III 3900 35 20 10 9 0 1.75 190 11.2 30 
59. Paneer Selvam 50 M III 7600 64 33 3 0 0 1.65 199 10.3 65 
60. Nazeema 30 F IV 8200 59 37 4 0 0 1.70 95 9 15 
61. Partha Sarathy 42 M IV 5800 66 25 9 0 0 1.2 52 10.6 10 
62. Elangovan 38 M III 4000 38 21 10 8 0 1.55 34 10.0 30 
63. Sara 33 F II 3900 39 21 11 7 0 1.60 356 10.5 35 
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Differential Count Sl. 
No. Name Age Sex 
WHO 
Stage 
Total 
count 
(per mm3) P% L% M% E% B%
Platelet 
Count  
(lakh/mm3)
CD4 
Count
(per µl)
Hb  
(g/dl) 
ESR  
at 1 hr 
64. Sivanandhan 42 M III 3600 60 36 4 0 0 1.0 121 12 12 
65. Irrison 52 M II 5800 45 46 9 0 0 2.1 41 10 14 
66. Babu 35 M II 6600 60 35 5 0 0 2.1 186 13.1 12 
67. Elumalai 39 M II 4100 38 21 10 7 0 1.0 50 10.0 10 
68. Kuppan 35 M III 7800 53 44 3 0 0 1.2 61 12 20 
69. Vijaya 28 F IV 2400 60 34 6 0 0 2.4 11 12 25 
70. Govindaraj 45 M II 5800 68 30 2 0 0 0.80 202 10.8 10 
71. Lakshmi Kanthamma 38 F II 7200 54 40 6 0 0  15 10.6 11 
72. Malliga 31 F III 9400 63 34 3 0 0 2.3 39 12.5 16 
73. Abdhul Razak 33 M III 9200 60 33 7 0 0 1.2 340 11.6 17 
74. Tamil Selvi 28 F III 6900 58 37 8 0 0 1.3 79 12.0 25 
75. Selvaraj 40 M III 4200 49 38 5 0 0 2.5 209 11 19 
76. Ramaswamy 54 M III 5200 68 30 2 0 0 1.1 29 12 30 
77. Srinivasan 40 M III 8000 60 37 3 0 0 0.65 173 12.6 30 
78. Gopal 32 M II 5800 68 30 2 0 0 2.0 134 14.0 35 
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Differential Count Sl. 
No. Name Age Sex 
WHO 
Stage 
Total 
count 
(per mm3) P% L% M% E% B%
Platelet 
Count  
(lakh/mm3)
CD4 
Count
(per µl)
Hb  
(g/dl) 
ESR  
at 1 hr 
79. Egambaram 32 M II 7600 69 29 2 0 0 2.4 386 13.5 40 
80. Sarasu 41 F III 5100 28 35 7 0 0 2.0 79 10.8 25 
81. Shanmugam 45 M III 8200 64 34 2 0 0 1.1 206 10.6 20 
82. Paul 35 M II 8800 68 28 7 0 0 3.0 91 9.7 15 
83. V. Kumar 48 M III 5300 68 38 7 0 0 1.2 302 10.6 40 
84. Kuppammal 27 F II 6800 56 40 7 0 0 2.1 70 10 35 
85. Krishnammal 35 F II 7200 56 40 7 0 0 1.4 200 10.2 36 
86. Uma 30 F II 9600 60 35 5 0 0 1.1 113 11.0 35 
87. Hema 45 F III 6000 60 33 7 0 0 2.0 9 10.2 40 
88. Dilli 35 F II 7000 59 27 4 0 0 1.0 72 8.0 35 
89. Soundarya 24 F III 6900 60 32 8 0 0 0.70 157 10.2 38 
90. Soundarammal 45 F IV 4800 46 50 4 0 0 0.75 81 13.4 16 
91. Samundeeswari 38 F III 9200 64 28 8 0 0 0.80 69 11.8 50 
92. Sridhar 34 M III 3900 63 28 9 0 0 2.6 49 8.3 15 
93. Kamala 45 F III 10200 70 25 5 0 0 1.6 180 11.8 20 
94. Sundar 35 M III 5400 70 24 6 0 0 1.7 145 11.8 25 
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Differential Count Sl. 
No. Name Age Sex 
WHO 
Stage 
Total 
count 
(per mm3) P% L% M% E% B%
Platelet 
Count  
(lakh/mm3)
CD4 
Count
(per µl)
Hb  
(g/dl) 
ESR  
at 1 hr 
95. Venkatesan 36 M IV 4200 80 19 1 0 0 1.4 138 10.6 26 
96. Manjula 32 F III 5800 45 46 9 0 0 1.3 140 10.0 19 
97. Kumar 43 M III 6500 51 44 5 0 0 1.2 197 13 20 
98. Gokila 34 F II 4300 55 43 2 0 0 1.8 147 9.6 25 
99. Alamelu 30 F II 8800 59 37 4 0 0 1.9 217 12 20 
100. Ramesh 28 M III 8400 49 41 10 0 0 1.0 211 12.6 20 
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PROFORMA 
Name :    Age :   Sex : 
Place :    Occupation : 
Hospital No. 
PRESENTING COMPLAINTS : 
PAST HISTORY : 
 H/o. Tuberculosis 
H/o. Exposure to a case of tuberculosis 
H/o. Drug intake 
H/o. Worm passage in stools 
H/o. Blood Transfusion 
PERSONAL HISTORY 
H/o. Alcohol intake 
H/o. Smoking 
H/o. IV Drug abuse 
H/o. Pre marital (or) extra marital exposure 
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GENERAL PHYSICAL EXAMINATION 
Built & Nourishment : 
Pallor :    Icterus :  Clubbing : 
Pedal Edema :   Lymph Nodes : 
Oral Candidiasis : 
Herpes Zoster : 
Glossitis : 
VITAL SIGNS : 
Pulse : 
Blood Pressure : 
Temperature : 
Respiratory Rate : 
CVS : 
RS : 
Abdomen : 
CNS : 
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INVESTIGATIONS 
Hemoglobin : Blood Sugar : 
Total Count : Urea: 
Differential Count : Creatinine 
CD4 Count : Electrolytes 
Platelet Count : LFT : 
ESR : 
Stool Examination : 
Urine Routine : 
Chest Xray : 
Sputum Examination : 
ELISA : 
Special Investigation : 
Final Diagnosis : 
